Axsome Therapeutics (AXSM) Cost of Revenue (2022 - 2026)

Axsome Therapeutics (AXSM) has 5 years of Cost of Revenue data on file, last reported at $14.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 50.42% year-over-year to $14.7 million; the trailing twelve-month figure through Mar 2026 stood at $52.4 million (up 42.45% YoY), and the FY2025 full-year result was $47.5 million, up 42.56% from the prior year.
• Cost of Revenue grew to $14.7 million in Q1 2026, from $12.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $14.7 million in Q1 2026 to a low of $983000.0 in Q2 2022.
• A 5-year average of $7.9 million and a median of $7.8 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue soared 367.85% in 2023 and declined 16.66% in 2024, its largest moves.
• Tracing AXSM's Cost of Revenue over 5 years: stood at $2.3 million in 2022, then jumped by 222.04% to $7.4 million in 2023, then soared by 42.5% to $10.5 million in 2024, then increased by 17.26% to $12.3 million in 2025, then gained by 19.43% to $14.7 million in 2026.
• Business Quant data shows AXSM's Cost of Revenue at $14.7 million in Q1 2026, $12.3 million in Q4 2025, and $11.9 million in Q3 2025.